Maraaz 
While global coronavirus cases exceed 20 million, vaccination studies are reaching the final stages. A study conducted in the USA showed that herd immunity was strengthened. Scientists think that the immune system’s memory cells also provide protection against the virus in the long term.
The immune system does not forget the corona virus, antibodies formed in the body of people who survive the disease provide protection in the long term.
This statement belongs to US researchers.
Scientists scrutinized cases seen on a fishing boat sailing from Seattle into the ocean.
COVID-19 was detected in 105 of the 122 crew members. It was seen that none of the sailors who had survived COVID-19 and had coronavirus antibodies in their blood were not infected.
Scientists think that what happened is also promising for herd immunity.
Current research shows that virus immunity in patients begins to decline within a few months.
Some experiments conducted in the United Kingdom revealed that T and B cells, which act as the memory of the immune system, provide “protection in the long term.”
The researchers say that for the vaccine to be developed to provide long-term protection, these cells must be activated.
On the other hand, vaccination studies continue without slowing down.
The UK vaccine task force signaled that the first registered vaccine could be produced before the end of the year.
Experts say that the vaccines developed in Oxford, England and Mainz, Germany are very close to the result.
Stage 3 tests of the vaccine developed at Oxford University continue in the UK, USA, Brazil and South Africa.
It is stated that the vaccine, which acts after two doses, does not completely prevent the disease and alleviates its course. 2 billion doses have already been ordered for the vaccine.
The tests of the vaccine, which was developed jointly by the German BionTech company with the American Pfizer, continue in the 3rd stage. This vaccine also needs 2 doses. 630 million doses were ordered from different countries of the world.
Tests for both vaccines are expected to be completed in October. However, experts emphasize that it is not known how effective the vaccines are or how long the protection will last.
